Back to Interventions
Substance / Medication

Dihydroergotamine

SNOMED 387267005UMLS C0012291

Overview

Active Ingredient
dihydroergotamine
RxNorm CUI
3418

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Orthostatic hypotension
Migraine
Postpartum hemorrhage
Hyposecretion of salivary gland
Cluster headache
Chronic cluster headache

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Recent Trials

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777Phase 4Completed64 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
Silberstein Stephen D, Shrewsbury Stephen B, Hoekman John · Headache · 2020
PMID: 31737909Meta-AnalysisFull text (PMC)
Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
Kellerman Donald J, Forst Amy, Combs Daniel L et al. · J Aerosol Med Pulm Drug Deliv · 2013
PMID: 23273242Meta-Analysis
Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
Morren John A, Galvez-Jimenez Nestor · Expert Opin Pharmacother · 2010
PMID: 21080856Meta-Analysis
Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature.
Colman Ian, Brown Michael D, Innes Grant D et al. · Ann Emerg Med · 2005
PMID: 15795718Meta-Analysis
A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
Lipton Richard B, Albrecht Detlef, Bermudez Maria et al. · Headache · 2024
PMID: 38413540RCT
Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
Bodie Susan, Curran Aidan K, Gonzalez-Nelson Aaron C et al. · Headache · 2024
PMID: 38717120RCT
MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.
Tepper Stewart J, Kori Shashidhar H, Goadsby Peter J et al. · Mayo Clin Proc · 2011
PMID: 21964172RCTFull text (PMC)
Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment.
Tso Amy R, Patniyot Irene R, Gelfand Amy A et al. · Neurology · 2017
PMID: 28615428ObservationalFull text (PMC)
Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
Tfelt-Hansen Peer · Headache · 2014
PMID: 24512579Observational
Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
Noveck Robert J, Douglas Pamela S, Chow Shein-Chung et al. · Drug Des Devel Ther · 2013
PMID: 23926420ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dihydroergotamine (substance)
SNOMED CT
387267005
UMLS CUI
C0012291
RxNorm CUI
3418

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

6
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.